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Abstract
Background: Health related quality of life (HRQOL) has increasingly emphasized on cancer patients. The
psychometric properties of the standard Chinese version of the European Organization for Research and Treatment
of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30, version 3.0) in brain tumor patients wasn’t
proven, and there was no baseline HRQOL in brain tumor patients prior to surgery.
Methods: The questionnaire EORTC QLQ-C30 (version 3.0) was administered at three time points: T1, the first or
the second day that patients were hospitalized after the brain tumor suspected or diagnosed by MRI or CT; T2, 1
to 2 days after T1, (T1 and T2 were both before surgery); T3, the day before discharge. Clinical variables included
disease histologic types, cognitive function, and Karnofsky Performance Status.
Results: Cronbach’s alpha coefficients for multi-item scales were greater than .70 and multitrait scaling analysis
showed that most of the item-scale correlation coefficients met the standards of convergent and discriminant
validity, except for the cognitive functioning scale. All scales and items exhibited construct validity. Score changes
over peri-operation were observed in physical and role functioning scales. Compared with mixed cancer patients
assessed after surgery but before adjuvant treatment, brain tumor patients assessed pre-surgery presented better
function and fewer symptoms.
Conclusions: The standard Chinese version of the EORTC QLQ-C30 was overall a valid instrument to assess HRQOL
in brain tumor patients in China. The baseline HRQOL in brain tumor patients pre-surgery was better than that in
mixed cancer patients post-surgery. Future study should modify cognitive functioning scale and examine test-retest
reliability and response validity.
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Cancers of the brain and nervous system account for
189,000 new cases and 142,000 deaths annually (1.7%
of new cancers and 2.1% of cancer deaths) [1]. Hence,
quality of life (QoL) issues are of special importance for
brain tumor patients. The European Organization for
Research and Treatment of Cancer (EORTC) Core
Quality of Life Questionnaire (QLQ-C30) [2] and the
Brain Cancer Module (BCM) [3], as well as the Func-
tional Assessment of Cancer Therapy-Brain (FACT-Br)
[4] were developed and extensively used in clinical trials.
T h em a j o r i t yo fQ o Li n s t r u m e n t sw e r ed e v e l o p e di n
English and used predominantly in English-speaking
populations. However in China, the study of health-
related quality of life (HRQOL) is still in the developing
stage. Most of QoL instruments used in China are trans-
lated from those used in developed English-speaking and
western European countries. The standard Chinese ver-
sion of EORTC QLQ-C30 (version 3.0) is, overall, a
valid instrument to assess HRQOL in Chinese breast,
gynecological, and lung cancer patients [5]; nevertheless,
its reliability and validity have not yet been evaluated in
brain tumor patients. To date, there is no specific brain
tumor questionnaire available to assess HRQOL in
China. Although HRQOL was extensively used as sec-
ondary endpoint to assess the efficacy of new treatments
after surgery [6-10], the baseline HRQOL in brain
tumor patients before surgery has never been investi-
gated, especially in China.
The objects of the study were: (1) to assess the relia-
bility and validity of the standard Chinese version of
QLQ-C30 (version 3.0) in brain tumor patients in
China; (2) to investigate the preoperative baseline
HRQOL in brain tumor patients; (3) to compare the
HRQOL discrepancies between patients before surgery
and those after surgery.
Methods
Participants
A consecutive series of patients with either suspected
brain tumor or diagnosed by MR or CT were recruited
from July 2008 to December 2008 in the Department of
Neurosurgery, Xijing Institute of Clinical Neuroscience,
Xijing Hospital, Fourth Military Medical University,
China. No restrictions were placed on patients’ selection
with regard to histologic type of brain tumors, age, edu-
cation, cognitive function or performance status. The
samples were restricted to patients who required surgi-
cal intervention. Post-operation patients with scheduled
radiotherapy or chemotherapy were excluded. The study
was approved by the Institutional Review Board of Xij-
ing Hospital, Fourth Military Medical University. Writ-
ten informed consent was obtained from each patient or
their legally authorized representative.
The Standard Chinese version of EORTC QLQ-C30
(version 3.0)
The EORTC QLQ-C30 (version 3.0) is a 30-item ques-
tionnaire composed of multi-item scales and single
items that reflect the multidimensionality of the QoL
construct. It includes five functional scales (physical,
role, cognitive, emotional, and social), three symptom
scales (fatigue, pain, and nausea/vomiting), and a global
health status/QoL scale. The remaining single items
assess additional symptoms commonly reported by can-
cer patients (dyspnea, appetite loss, sleep disturbance,
constipation, and diarrhea), as well as the perceived
financial impact of the disease and treatment [11].
Description of Procedures or Investigations undertaken
The standard Chinese version of QLQ-C30 (version 3.0)
was administered at three timep o i n t s :T 1( t h ef i r s to r
the second day that patients were hospitalized in our
hospital, but before surgery) to evaluate all eligible
patients; T2 (1 to 2 days later after T1 but before sur-
gery) to patients who were randomly selected from
patients at T1 using computer-generated random table
number; T3 (the day before discharge which is after sur-
gery), to evaluate patients who were randomly selected
from patients at T1 using computer-generated random
table number. Scoring of the Chinese version of the
Mini-Mental State Examination (MMSE) [12] and Kar-
nofsky Performance Status( KPS) [13] was performed by
the doctors or nurses at the time of the first administra-
tion of the QLQ-C30. MMSE and KPS are used as
grouping variables.
Statistical methods
Based on MMSE scores, patients were divided into nor-
mal cognition and abnormal cognition groups [12,14].
Concisely, MMSE scores less than 18 in illiterate
patients, less than 21 in patients with elementary school
education, and less than 25 in patients with more than
high school education were defined as indicating abnor-
mal cognition. Scoring of the responses to the QLQ-
C30 (version 3.0) was carried out according to pre-
viously published procedures’ [2,15]. The raw scores for
each domain and single item were transformed to give a
value between 0-100. For the five functional scales and
the global health status/QoL scale, item responses were
recorded so that a higher score represented a better
level of functioning. For the symptom-oriented scales
and items, a higher score corresponded to a severe level
of symptoms. If there was no specific indication, all the
data for analysis of QLQ-C30 were from T1 administra-
tion of it. The postulated scale structure was analyzed
for scaling errors using multitrait scaling analysis [2].
Internal consistency reliability of multi-item scales was
demonstrated by Cronbach’s alpha coefficient [2]. The
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Pearson’s Correlation Coefficient [16]. Three approaches
were taken to evaluate the validity of the QLQ-C30.
Correlations were determined by Pearson’sC o r r e l a t i o n
Coefficient, comparison of differences within known-
groups was calculated by ANOVA (for cross-sectional
analysis of T1), and the responsiveness of the QLQ-C30
to changes in health status over surgery was evaluated
by repeated measures ANOVA (for analysis of the
change between T1 and T3) [2]. The known-groups
were classified according to age, sex, cognition, KPS,
and tumor types. Comparison of distribution differences
between data from brain tumors and reference data
from all cancer patients was done using Mann Whitney
U-test [17]. The reference data is available from the
EORTC Quality of Life Department. Statistical signifi-
cance was defined as P < .05. All of the tests were two
sided. Statistical analysis was performed using the SPSS
software package, version 16.0 (SPSS Inc, Chicago, IL,
USA).
Results
There were 366 patients enrolled in the study. After
excluding 6 patients who died in peri-operation period,
28 patients with pathologically confirmed non-tumors,
24 patients with significant data loss or errors, and a
total of 308 patients were recruited into the current sta-
tistical analysis. Of these 308 patients, 66 (21.4%) ran-
domly selected patients completed the questionnaire at
both T1 and T2, 53 (17.2%) completed the questionnaire
at both T1 and T3. All of the 308 patients were
included in T1. There was no statistically significant dif-
ference concerning the demographic and clinical data
between T1 population and T2 or T3 samples. The
length of hospital stay was 18 ± 6 days, and the post-
operative length of hospital stay was 15 ± 7 days. The
clinical characteristics of all the samples were reported
in Additional file 1. The sample was heterogeneous
regarding to histologic type of brain tumors, cognitive
function and KPS.
Acceptability of the Questionnaire
The average time required to complete the standard
Chinese version of QLQ-C30 (version 3.0) was 13-14
minutes (SD = 12 minutes). Of total 308 patients at T1,
127 patients (41.2%) were able to complete the ques-
tionnaire without assistance (self-report), 29 patients
(9.4%) and 102 patients (33.1%) were able to complete
the questionnaire aided by nurses or family members
respectively (self-report required assistance), 32 patients
( 1 0 . 4 % )w e r eu n a b l et oc o m p l e t et h eq u e s t i o n n a i r e
therefore the family members reported the question-
naires (proxy-report), 18 patients (5.8%) were not
recorded the reporters. Of the reasons for the patients’
questionnaires whose were self report required assis-
tance and proxy report, 26.1% was that the patients
could not understand the actual language/illiterate,
25.0% was administrative failure to distribute the ques-
tionnaire to the patient, 18.6% was the patients’ visual
disorder, 15.4% was that the patients felt it was inconve-
nient or took too much time, 8.0% was that the patients
felt themselves too ill, 6.9% was that the clinician or
nurse felt the patient was too ill. No matter what the
mode of administration was, all the questionnaires were
included in the flowing analysis. In patients with abnor-
mal cognition, the proxy-report rate (16/53) and self-
report required assistance rate (24/53) were higher than
that in patients with normal cognition (proxy-report
rate 14/230, self-report required assistance rate 104/
230). The self-report rate in patients with abnormal cog-
nition was lower than that in patients with normal cog-
nition (patients with abnormal cognition vs. normal
cognition: 13/53 vs. 112/230) Controlling for patients’
KPS, no statistically significant differences were noted in
most of scales and items response dispersion (means
and standard deviations), among those who were self-
report, self-report required assistance and proxy-report.
Since that only a very small proportion of patients with
abnormal cognition had completed questionnaires by
themselves (13 vs. 308), and that not every clinical trial
performed cognition assessment to distinguish such
patients, we did not exclude them from analysis.
Multitrait Scaling
Item-scale correlations (corrected for overlap) exceeded
the .40 criterion for item-convergent validity for seven
of the nine hypothesized scales at T1. (Exceptions
included one item from the emotional functioning scale
and both items from the cognitive functioning scale.)
The mean item-scale correlations across all nine scales
were .58. There were 192 tests of item-discriminant
validity (data not shown) for T1 administration. Scaling
successes were noted in 97% of the cases. Taken
together, the very small number of scaling errors pro-
vided strong support for the hypothesized scale struc-
t u r eo ft h eQ L Q - C 3 0 .T h eo n l ys c a l et h a ti n d i c a t e d
consistent problems was the cognitive functioning scale.
Descriptive Statistics and Scale Reliability
Table 1 shows the means, standard deviations, median
and mode for the multi-item and single-item measures
for T1 administrations of the standard Chinese version
of QLQ-C30 (version 3.0). Additional file 2 shows con-
structed scales and items of all brain tumor patients
before surgery. The full range of possible scores was
observed for all measures at T1 except for the emotional
functioning scale (range, 17-100) and diarrhea item
(range, 0-67). Only the global health status/QoL showed
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negative skew distribution in all functioning scales and
the modal scores were frequently 100 (i.e., more patients
scored toward maximum functioning). The symptom
scales and single-item measures were generally positive
skew distribution and the modal scores were frequently
0 (i.e., no symptoms), except that the modal scores of
fatigue and mode were 33.3. As expected, constipation
and diarrhea symptoms that not specifically associated
with brain tumor patients were not reported frequently.
Eight of the nine multi-item subscales met the minimal
standards of reliability (range from .75 to .91 at T1,
Cronbach’s alpha coefficient >.70), except for the cogni-
tive functioning scale (.33). (Table 1)
Pearson’s correlation coefficients among all nine scales
and seven items of the QLQ-C30 for both the T1 and T2
administration were statistically significant (role and
emotional functioning scales p < .05, others p < .001);
however, the reproducibility of the questionnaire was not
satisfactory (Pearson’s r < .80, physical function, global
health status/QoL, fatigue, pain, finance scales’ Pearson’s
r .50 - .79, other scales’ Pearson’s r .27 - .50).
Validity of the QLQ-C30
In the following sections, the results of the three types
of validity analysis outlined in the “Methods” section are
presented.
Inter-scale correlations
Table 2 presents the correlations among the nine scales
of the QLQ-C30 for both the T1 and T3 administrations.
Some inter-scale correlations were statistically significant
(p < .05), reflecting both the conceptual non-orthogonal-
ity of the scales and the effect of a relatively large sample
size. The magnitude of these correlations is more impor-
tant. The strongest correlations both before and after sur-
gery were observed between the physical functioning and
fatigue scales (ranging from -.58 to -.54). The global
health status/QoL scale and fatigue scales were correlated
with most of the other scales; whereas, no correlation
was observed between the emotional functioning scale
and the physical, role and cognitive functioning scales,
between cognitive functioning scale and emotional func-
tioning, social functioning and pain scales, between social
functioning scale and cognitive functioning, nausea/
vomiting, and global health status/QoL scales, between
nausea/vomiting scale and role and social functioning
scales. Most of other scales were correlated moderately
or weakly with each other. In general, the inter-scale cor-
relations of only a moderate or weak size indicated that,
although related, they were able to reflect distinct compo-
nents of the QoL construct.
Clinical validity–known-groups comparisons
No statistically significant difference was observed
between male and female. As expected, patients older
Table 1 Descriptive statistics and scale reliability of the QLQ-C30
Items* Mean Median Mode SD Cronbach’s alpha
coefficient$
Functioning scales^
PF 1-5 81.0 86.7 100.0 23.23 0.88
RF 6, 7 79.4 100.0 100.0 28.30 0.91
EF 21-24 78.0 83.3 100.0 18.40 0.80
CF 20, 25 76.2 83.3 100.0 20.95 0.33
SF 26, 27 70.7 66.7 100.0 27.74 0.80
QL 29, 30 54.7 58.3 67.0 26.55 0.85
Symptom scales and/or items§
FA 10, 12, 18 31.2 33.3 33.0 23.71 0.81
NV 14, 15 11.3 0.0 0.0 20.91 0.84
PA 9, 19 26.5 16.7 0.0 26.33 0.75
DY 8 10.8 0.0 0.0 19.72
SL 11 18.5 0.0 0.0 28.60
AP 13 19.9 0.0 0.0 28.09
CO 16 14.5 0.0 0.0 24.19
DI 17 2.8 0.0 0.0 10.03
FI 28 47.1 33.3 33.0 36.33
* Numbers correspond to the item numbers in the questionnaire.
$ Alpha values >.70 indicate adequate scale reliability.
^ Scores range from 0 to 100, with a higher score representing a higher level of functioning.
§Scores range from 0 to 100, with a higher score representing a greater degree of symptoms.
Abbreviations: AP Appetite loss, CF Cognitive functioning; CO Constipation; DI Diarrhoea; DY Dyspnoea; EF Emotional functioning; FA Fatigue; FI Financial
difficulties; NV Nausea and vomiting; PA Pain; PF physical function; QL Global health status; RF role function; SF Social functioning; SD standard deviation; SL
Insomnia
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.035) and cognitive (p = .001) functioning, worse global
health status/QoL (p = .001), more symptoms of sleep
(p = .025) and appetite loss (p = .021) than those
younger than 50. Patients with normal cognition had
better physical (p = .001) and cognitive (p < .001) func-
tioning, better global health status/QoL (p = .007), less
fatigue (p = .045) and appetite loss (p = .008) symptoms
than those with abnormal cognition. (Figure 1A and 1B)
Differences of the remaining scales and single-item mea-
sures, though not statistically significant, were all in the
expected direction between different age groups or cog-
nitive groups. Patients with KPS 80 - 100 showed statis-
tically significant higher functional and lower symptom
scores than those with KPS less than 80 (Figure 1C and
1D). Though the incidence of dyspnea, constipation and
diarrhea didn’t show statistical significance, they were
reported more frequently in patients with KPS less than
80. Grouping by brain tumor types, statistically signifi-
cant differences were found in role and social function-
ing scales, global health status/QoL, and pain, dyspnea,
and appetite loss symptom scales/items (p < .05). There
was a trend that patient with metastatic brain tumors
reported the lowest levels for most functioning, worst
global health status/QoL, and highest levels for most
symptoms, followed by glioma, meningioma, pituitary
adenoma and cholesteatoma. (Figure 1E and 1F) Patients
with craniopharyngioma, schwannoma, and other
tumors did not follow this trend because of limited
number or heterogeneous populations. (The item asses-
sing diarrhea was excluded from these analyses because
of the low frequency of this symptom reported in the
total sample; the item on financial impact was excluded
because of the absence of explicit hypotheses regarding
its association with the grouping variables.)
Clinical validity–responsiveness to changes over surgery
Statistically significant changes between assessments
before and after surgery were only found in the physical
and role functioning scales and financial difficulties
item. Higher mean scores were observed in the physical
and role functioning scales before surgery than after
surgery (mean = 75.8 vs. 63.1, p = .003; mean = 71.7 vs.
58.8, p = .007, respectively).
Comparison of individual brain tumor patient’s score with
reference value
Considering the absence of physical functioning reference
data of brain tumor provided by EORTC QLQ-C30 and
that surgery has a significant deleterious impact on
patients’ physical functioning for a short time, we could
only compare our data from brain tumor patients with
the reference data from all cancer patients [17]. Patients
with brain tumors showed better physical, role, emotional
functioning(p < .0001), worse cognitive and social func-
tioning (p < .0001) and global health status/QoL (p <
.0001), more nausea and vomiting symptoms (p < .05),
less dyspnea, insomnia and diarrhea (p < .0001) than
those in reference data.
Discussion
Previous studies of the EORTC QLQ-C30 showed its
validity and reliability across various countries [2], so
did the standard Chinese version of the QLQ-C30 (ver-
sion 3.0) in lung, gynecological, and breast cancer
patients [5]. Here we presented for the first time the
results of a study applying the standard Chinese version
of the QLQ-C30 (version 3.0) in brain tumor patients.
The questionnaire was well accepted by the patients. It
cost 13-14 minutes to complete on average, and could
be filled out by the patients themselves with little or no
Table 2 Correlations among the QLQ-C30 scales before and after operation
PF RF EF CF SF QL FA NV PA
PF .789** .306* 0.12 .352** .267* 0.24 -.580** -0.24 -.427**
RF .474** .288* 0.21 .355** .551** .350** -.366** -0.20 -.353**
EF -0.04 -0.01 .272* 0.21 0.10 .334** -0.01 -.270* -.283*
CF .331** 0.12 0.23 .454** 0.20 .263* -.330** -.357** -0.24
SF 0.18 0.18 .321** 0.22 .391** 0.22 -0.22 -0.18 -.448**
QL .381** .315* .272* .254* 0.21 .607** -.489** -.357** -.616**
FA -.540** -.352** -.331** -.538** -.322** -.402** .697** .304* .580**
NV -.243* 0.01 0.07 0.01 -0.04 -.245* 0.20 .367** .406**
PA -.383** -0.14 -0.15 -0.21 -.307* -.346** .296* .316** .610**
# Before operation under the diagonal; after operation above the diagonal. Values = Pearson’s r. Negative correlations are an artifact of the scoring procedures.
For the functional scales (PF, RF, CF, EF, SF, and QL), a higher score represents a higher level of functioning. For the symptom scales (FA, NV, and PA ), a higher
score represents a higher level of symptoms. All correlation coefficients are statistically significant.
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
Abbreviations: CF Cognitive functioning; EF Emotional functioning; FA Fatigue; NV Nausea and vomiting; PA Pain; PF physical function; QL Global health status;
RF role function; SF Social functioning
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Page 5 of 9Figure 1 Summary of ANOVA results of QLQ-C30 grouped by preoperative cognition (n = 297), by KPS (n = 266) and by brain tumor
types (n = 304). ***. Correlation is significant at the .001 level (2-tailed). **. Correlation is significant at the .01 level (2-tailed). *. Correlation is
significant at the .05 level (2-tailed). Abbreviations: AP appetite loss, CF cognitive functioning; Cho cholesteatoma; CO constipation; Cra
craniopharyngioma; DI diarrhea; DY dyspnea; Abnormal abnormal cognition; EF emotional functioning; FA fatigue; FI financial difficulties; KPS70
KPS ≤ 70; KPS80 KPS ≥ 80; NV nausea/vomiting; Normal normal cognition; PA pain; Pit pituitary adenoma; QL global health status/quality of life;
SF social functioning; SL insomnia
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that proxy could only be used when the information
cannot be sought by self report from the patients. How-
ever, according to our results, controlling the KPS, the
mode of administration (self-report, self-report required
assistance and proxy-report) did not appear to influence
the distributions of the scores. This was especially
important to assess the HRQOL in brain tumor patients
who suffered visual disorder or abnormal cognition or
who were illiterate or children, thus it supported the
possibility of large-scale clinical application of the
questionnaire.
Multitrait scaling analysis showed that most of the
item-subscale correlation coefficients met the standards
of convergent and discriminant validity. Eight of the
nine multi-item subscales met the minimal standards of
reliability. Similar to the previous studies [5,16], the
results of multitrait scaling analysis and Cronbach’s
alpha coefficients of the cognitive functioning subscale
were questionable. There are two items to assess cogni-
tive function (Have you had difficulty in concentrating
on things, such as focusing on reading a newspaper or
watching television? Have you had difficulty in remem-
bering things?). Despite the notions that memory and
concentration appear to be two distinctive aspects of
cognitive functioning, a single composite index of the
overall cognitive functioning scale would probably have
general clinical utility. During the investigation, we
found many patients with poor vision were misguided
by the expression of “such as reading a newspaper or
watching television”. Therefore, in the future study, this
explanation of concentrating should be changed. The
different result between Chinese and others was caused
by the language and culture difference. The test-retest
reliability of the questionnaire was not so satisfactory as
previous report [5]. One possible explanation was that
these newly diagnosed brain tumor patients did not
have much knowledge of their diseases on their initial
admission but they got to know more of the severity of
the diseases and bad prognosis in the following days,
which was especially true and common in China.
Besides, patients may have symptoms relief due to medi-
cation installed such as corticosteroids at the T2. All
these may psychologically change their subjective assess-
ments on their QoL, which was manifested by the bad
reproducibility. Other time points for documenting the
test-retest are needed.
The descriptive statistics indicated 100 as the mode of
all the functioning scales and 0 as the mode in most of
the symptom scales/items (except for fatigue scale and
financial difficulty item) before surgery. These results
were different from other reports whose score distribu-
tions were roughly symmetrical for the majority of the
functioning scales and whose score distributions were
generally well distributed for the symptom scales and
single-item measures, despite that the modal scores
were frequently 0 [2]. However, the distributions of our
data showed some similarity to those reported by Zhao
et al [5]. Compared with reference data from all cancer
patients [17], brain tumor patients reported significantly
better physical, role, emotional functioning, worse cog-
nitive and social functioning and global health status/
QoL, more nausea/vomiting symptoms, less dyspnoea,
insomnia and diarrhea. These disparities may be attribu-
ted to the different time of administration of the ques-
tionnaire (before vs. after surgery), to different types of
cancer and to different culture. Surgery was likely to
temporarily bring about decreased physical, role and
emotional functioning, and increased symptoms. Differ-
ent diseases had different effect on HRQOL. Brain
tumor patients presented more severely abnormal cogni-
tion than other cancers because the tumor directly
destroyed the brain tissues which were responsible for
cognition.
The majority of the functional and symptom measures
were able to distinguish clearly between patients differ-
ing in terms of age (age > = 50, age < 50), cognition
(normal cognition, abnormal cognition), KPS (KPS > =
80, KPS < 80), and among patients different brain tumor
types. There was a trend that metastatic brain tumors
were associated with worst functioning and most severe
symptoms, followed by glioma, meningioma and pitui-
tary adenoma. This tendency probably reflected the dif-
ferent aggressiveness of the brain tumors. The QLQ-
C30 was significantly deteriorated in physical and role
functioning over surgery (T1 vs.T3), while had little
change in other scales and items. This may not only be
attributed to poor validity of the QLQ-C30, but also
because surgery could temporarily limit the patients’
activity then change their physical and role functioning
which need much longer time to recover after discharge,
but not have direct and main effect on other function-
ing, symptoms, and a global health status/QoL scale.
Similar phenomena were also found in other clinical
trials, which showed little change of HRQOL in patients
undergoing different treatments [18-21]. The factors
affecting HRQOL are complicated, including age, sex,
location and classification of tumor, moods, treatment
strategies, expectation and experience, the relationship
of patients and so on [6]. Besides, multidimensional
HRQOL questionnaires containing too many items that
interact with each other may counteract some effect.
For comparing the effects of treatments after surgery,
the baseline HRQOL after surgery but before adjuvant
treatment was more practical as many previous trials
chose [21-24]. However, to compare the conservation
therapies with surgery or between different surgical stra-
tegies, the baseline HRQOL before surgery is also
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but before adjuvant treatment could predict the patients’
prognosis [25]. Therefore whether the HRQOL before
surgery can indicate the prognosis is also worth studying.
Conclusions
In conclusion, our study for the first time provided a
baseline the standard Chinese version QLQ-C30 (ver-
sion 3.0) score in brain tumor patients before surgery.
The questionnaire can effectively discriminate the
known-group patients. However, its test-retest reliability
and response validity need to be further investigated,
and the cognitive functioning scale might need to be
modified in Chinese version. Since there was no Chinese
version of brain tumor specific module (such as BCM)
available, the study on HRQOL in brain tumor patients
only using the standard Chinese version of QLQ-C30
(version 3.0) may lose sufficient brain tumor specific
information. In the future, the brain tumor specific
questionnaire should be formulated for brain tumor
patients in China.
Additional material
Additional file 1: Clinical characteristics of the study samples. T1, the
first or the second day that patients were hospitalized in our hospital,
but before surgery, for all eligible patients; T2, following 1 to 2 days of
T1, but before surgery, for randomly selected eligible patients; T3. the
day before patients discharged (15 ± 7 days after surgery), for randomly
selected eligible patients.
# contains 2 chordoma, 1 fibroma
sarcomatosum, 2 germinoma, 1 haemangioma, 4 hemangioblastoma, 1
hemanyiopericytoma, 1 lymphoma, 4 medulloblastoma, 1 primitive
neuroectodermal tumor, 1 solitary fibrous tumor, 1 spindle cell
oncocytoma, 2 trigeminal neurinoma, 20 tumor without pathological
demonstration.
Additional file 2: All brain tumor patients constructed scales and
items (before surgery). Abbreviations: AP Appetite loss, CF Cognitive
functioning; CO Constipation; DI Diarrhoea; DY Dyspnoea; EF Emotional
functioning; FA Fatigue; FI Financial difficulties; NV Nausea and vomiting;
PA Pain; PF physical function; QL Global health status; RF role function;
SF Social functioning; SD standard deviation; SL Insomnia.
List of abbreviations
BCM: Brain Cancer Module; CF: cognitive functioning; Cho: cholesteatoma;
CO: constipation; Cra: craniopharyngioma; DI: diarrhea; DY: dyspnoea; EF:
emotional functioning; EORTC: European Organization for Research and
Treatment of Cancer; FA: fatigue; FACT-Br: Functional Assessment of Cancer
Therapy-Brain; FI: financial difficulties; HRQOL: health related quality of life;
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